Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Google Secures Pentagon AI Deal for Classified Projects 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
BERKELEY, Calif., April 25, 2017 -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present at the following investor conferences in May 2017:
- 42nd Annual Deutsche Bank Health Care Conference in Boston, MA on Wednesday, May 3, 2017 at 8:00 am Eastern Time
- Bank of America Merrill Lynch 2017 Heath Care Conference in Las Vegas, NV on Thursday, May 18, 2017 at 10:00 am Pacific Time
To access the live webcasts and subsequent archived recordings of these and other company presentations, please visit Aduro's website at www.aduro.com.
About Aduro
Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro's technology platforms, which are designed to harness the body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro's LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. This platform is being developed as a treatment for multiple indications, including mesothelioma, ovarian, lung and prostate cancers. Additionally, a personalized form of LADD, or pLADD, is being developed utilizing tumor neoantigens that are specific to an individual patient’s tumor. Aduro's STING Pathway Activator platform is designed to activate the STING receptor in immune cells, resulting in a potent tumor-specific immune response. ADU-S100 is the first STING Pathway Activator compound to enter the clinic and is currently being evaluated in a Phase 1 study in patients with cutaneously accessible metastatic solid tumors or lymphomas. Aduro’s B-select monoclonal antibody platform includes a number of immune modulating assets in research and preclinical development. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms. For more information, please visit www.aduro.com.
Contact: Sylvia Wheeler SVP, Corporate Affairs 510 809 9264 Media Contact: Susan Lehner 510 809 2137 [email protected]
